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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Combination Antifungal Therapy for Cryptococcal Meningitis
To the Editor: In the trial of combination ther-
apy for cryptococcal meningitis in patients with 
human immunodeficiency virus infection, Day 
et al. (April 4 issue)1 found a survival benefit as-
sociated with 2 weeks of therapy with amphoter-
icin B and flucytosine as compared with ampho-
tericin B monotherapy. The results of this trial 
reinforce the treatment combination as the stan-
dard per current guidelines.2,3 In locations where 
amphotericin B therapy is not feasible, flucyto-
sine is recommended in combination with flu-
conazole.2-4 However, the availability of flucyto-
sine worldwide remains grossly inadequate.
Flucytosine is currently unregistered and un-
available in most of Asia and Africa, where the 
disease burden is greatest.5 Even though flucyto-
sine is a simple, orally administered, off-patent 
drug, only two manufacturers have been approved 
by the Food and Drug Administration: the origi-
nator company, Meda Pharmaceuticals, and the 
generic manufacturer, Sigmapharm Laboratories. 
The lack of data about disease burden, concerns 
regarding toxicity, and high drug costs due to a 
lack of competition have contributed to a market 
failure for flucytosine.5 Given the findings of 
Day et al., sustained efforts from governmental 
and international stakeholders are now required 
in order to urgently disseminate and implement 
World Health Organization (WHO) treatment 
guidelines, facilitate the registration of flucyto-
sine, motivate generic-drug production, stimu-
late development of sustained-release formula-
tions of f lucytosine, and widen access to this 
drug.3,5
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The Authors Reply: We agree with Loyse et al. 
that increasing access to flucytosine could re-
duce deaths from cryptococcal meningitis. In 
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our study, flucytosine levels were not monitored, 
but patients had regular blood counts and elec-
trolyte and creatinine measurements. We showed 
that in a resource-constrained setting, in combi-
nation with amphotericin B, flucytosine can be 
used safely and increases both survival and fun-
gal clearance. Patients receiving the combination 
treatment had similar rates of adverse events as 
those receiving amphotericin B monotherapy. 
Fluconazole combined with flucytosine, recom-
mended as second-line treatment by the WHO, is 
an attractive treatment for cryptococcal meningi-
tis because of ease of administration.1 Flucona-
zole is cheaper than amphotericin B and has a 
favorable toxicity profile. However, amphotericin 
B–sparing combinations consistently show lower 
rates of yeast clearance from cerebrospinal fluid 
— early fungicidal activity — than those con-
taining amphotericin B.2 Bicanic and colleagues 
found that early fungicidal activity was closely 
correlated with survival.3 Therefore, in addition 
to improving access to flucytosine, it is impera-
tive that stakeholders work to improve the avail-
ability of, and the capacity to safely administer, 
amphotericin B.
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Ischemic Heart Disease after Breast Cancer Radiotherapy
To the Editor: In their analysis of ischemic 
heart disease in a Nordic cohort of survivors of 
breast cancer, Darby et al. (March 14 issue)1 ob-
serve a significant excess relative risk associated 
with radiotherapy, which is concordant with the 
risks seen in other radiotherapy-treated groups2,3 
(Table 1). This finding suggests that the mean 
dose to the heart is the most relevant metric for 
predicting radiation-associated ischemic heart 
disease. The findings about the radiation risks 
also agree with those of a recent meta-analysis4 
of low-to-moderate radiation exposure (Table 1), 
implying little sparing effect of low doses and 
protracted radiation exposures. The comprehen-
sive analysis by Darby et al. of other risk factors 
for ischemic heart disease suggests minimal in-
teraction with radiogenic risk, again consistent 
with (more limited) observations reviewed else-
where.4
All these findings suggest that there is excess 
ischemic heart disease associated with high 
(therapeutic) and low (diagnostic) doses of ra-
diation. Although there has been concern about 
increased risks of cancer associated with com-
puted tomographic (CT) angiograms and coro-
nary-artery calcium scans,6 the evidence pre-
sented by Darby et al. and elsewhere5 strongly 
suggests that clinicians should also be con-
cerned with cardiovascular morbidity and should 
limit the dose of radiation affecting the heart.
Mark P. Little, D.Phil.
National Cancer Institute 
Bethesda, MD 
mark.little@nih.gov
Lydia B. Zablotska, Ph.D.
University of California, San Francisco, School of Medicine 
San Francisco, CA
Steven E. Lipshultz, M.D.
University of Miami Miller School of Medicine 
Miami, FL
No potential conflict of interest relevant to this letter was re-
ported.
1. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart 
disease in women after radiotherapy for breast cancer. N Engl J 
Med 2013;368:987-98.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on April 12, 2019. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
